Do analysts recommend ZVSA or SPRC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, ZVSA or SPRC?

ZyVersa Therapeutics has higher earnings, but lower revenue than SciSparc. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ZyVersa Therapeutics N/A N/A -$9.41M -$0.83 N/A SciSparc $856K 5.37 -$12.18M N/A N/A

Is ZVSA or SPRC more profitable?

SciSparc's return on equity of 0.00% beat ZyVersa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets ZyVersa Therapeutics N/A -109.54% -43.95% SciSparc N/A N/A N/A

Do analysts rate INM or ZVSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate ZVSA or GELS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, ZVSA or GELS?

Gelteq has higher revenue and earnings than ZyVersa Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ZyVersa Therapeutics N/A N/A -$9.41M -$0.83 N/A Gelteq $110K 107.59 -$4.30M N/A N/A

Is ZVSA or GELS more profitable?

Gelteq's return on equity of 0.00% beat ZyVersa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets ZyVersa Therapeutics N/A -109.54% -43.95% Gelteq N/A N/A N/A

Do analysts recommend RDHL or ZVSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is RDHL or ZVSA more profitable?

Redhill Biopharma's return on equity of 0.00% beat ZyVersa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Redhill Biopharma N/A N/A N/A ZyVersa Therapeutics N/A -109.54% -43.95%

Do analysts prefer FLGC or ZVSA?

Flora Growth currently has a consensus target price of $30.00, indicating a potential upside of 557.89%. Given Flora Growth's stronger consensus rating and higher possible upside, equities research analysts clearly believe Flora Growth is more favorable than ZyVersa Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Flora Growth 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

ZyVersa Therapeutics (ZVSA) Competitors

$0.20 0.00 (0.00%)

As of 01:08 PM Eastern

Compare

ZVSA vs. SPRC, INM, GELS, RDHL, and FLGC

Should you buy ZyVersa Therapeutics stock or one of its competitors? MarketBeat compares ZyVersa Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ZyVersa Therapeutics include SciSparc (SPRC), InMed Pharmaceuticals (INM), Gelteq (GELS), Redhill Biopharma (RDHL), and Flora Growth (FLGC). These companies are all part of the "pharmaceutical products" industry.

How does ZyVersa Therapeutics compare to SciSparc?

ZyVersa Therapeutics (NASDAQ:ZVSA) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

SciSparc's return on equity of 0.00% beat ZyVersa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZyVersa Therapeutics	N/A	-109.54%	-43.95%
SciSparc	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

3.9% of ZyVersa Therapeutics shares are held by institutional investors. Comparatively, 25.1% of SciSparc shares are held by institutional investors. 0.2% of ZyVersa Therapeutics shares are held by insiders. Comparatively, 1.5% of SciSparc shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ZyVersa Therapeutics has higher earnings, but lower revenue than SciSparc.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A
SciSparc	$856K	5.37	-$12.18M	N/A	N/A

In the previous week, SciSparc had 3 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 3 mentions for SciSparc and 0 mentions for ZyVersa Therapeutics. SciSparc's average media sentiment score of 0.96 beat ZyVersa Therapeutics' score of 0.00 indicating that SciSparc is being referred to more favorably in the news media.

Company	Overall Sentiment
ZyVersa Therapeutics	Neutral
SciSparc	Positive

ZyVersa Therapeutics has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, SciSparc has a beta of 2.74, suggesting that its stock price is 174% more volatile than the broader market.

Summary

SciSparc beats ZyVersa Therapeutics on 9 of the 10 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to InMed Pharmaceuticals?

InMed Pharmaceuticals (NASDAQ:INM) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

ZyVersa Therapeutics has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. InMed Pharmaceuticals' return on equity of -80.85% beat ZyVersa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
ZyVersa Therapeutics	N/A	-109.54%	-43.95%

In the previous week, InMed Pharmaceuticals had 13 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 13 mentions for InMed Pharmaceuticals and 0 mentions for ZyVersa Therapeutics. InMed Pharmaceuticals' average media sentiment score of 1.14 beat ZyVersa Therapeutics' score of 0.00 indicating that InMed Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
InMed Pharmaceuticals	Positive
ZyVersa Therapeutics	Neutral

InMed Pharmaceuticals has higher revenue and earnings than ZyVersa Therapeutics. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than ZyVersa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	1.00	-$8.16M	-$2.89	N/A
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A

20.1% of InMed Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are owned by institutional investors. 0.9% of InMed Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

InMed Pharmaceuticals has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, ZyVersa Therapeutics has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market.

Summary

InMed Pharmaceuticals beats ZyVersa Therapeutics on 9 of the 13 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to Gelteq?

ZyVersa Therapeutics (NASDAQ:ZVSA) and Gelteq (NASDAQ:GELS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

Gelteq's return on equity of 0.00% beat ZyVersa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZyVersa Therapeutics	N/A	-109.54%	-43.95%
Gelteq	N/A	N/A	N/A

In the previous week, Gelteq had 18 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 18 mentions for Gelteq and 0 mentions for ZyVersa Therapeutics. Gelteq's average media sentiment score of 0.30 beat ZyVersa Therapeutics' score of 0.00 indicating that Gelteq is being referred to more favorably in the news media.

Company	Overall Sentiment
ZyVersa Therapeutics	Neutral
Gelteq	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ZyVersa Therapeutics has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, Gelteq has a beta of -0.19, meaning that its share price is 119% less volatile than the broader market.

Gelteq has higher revenue and earnings than ZyVersa Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A
Gelteq	$110K	107.59	-$4.30M	N/A	N/A

3.9% of ZyVersa Therapeutics shares are held by institutional investors. 0.2% of ZyVersa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Gelteq beats ZyVersa Therapeutics on 7 of the 10 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to Redhill Biopharma?

Redhill Biopharma (NASDAQ:RDHL) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

7.2% of Redhill Biopharma shares are owned by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Redhill Biopharma had 4 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 4 mentions for Redhill Biopharma and 0 mentions for ZyVersa Therapeutics. Redhill Biopharma's average media sentiment score of 0.37 beat ZyVersa Therapeutics' score of 0.00 indicating that Redhill Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Redhill Biopharma	Neutral
ZyVersa Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Redhill Biopharma's return on equity of 0.00% beat ZyVersa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
ZyVersa Therapeutics	N/A	-109.54%	-43.95%

Redhill Biopharma has a beta of 4.98, indicating that its share price is 398% more volatile than the broader market. Comparatively, ZyVersa Therapeutics has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

Redhill Biopharma has higher revenue and earnings than ZyVersa Therapeutics. ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$286K	14.52	-$430K	$1.05 thousand	0.00
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A

Summary

Redhill Biopharma beats ZyVersa Therapeutics on 12 of the 12 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to Flora Growth?

Flora Growth (NASDAQ:FLGC) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

Flora Growth currently has a consensus target price of $30.00, indicating a potential upside of 557.89%. Given Flora Growth's stronger consensus rating and higher possible upside, equities research analysts clearly believe Flora Growth is more favorable than ZyVersa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

ZyVersa Therapeutics has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Flora Growth's return on equity of -64.02% beat ZyVersa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Flora Growth	-32.03%	-64.02%	-34.46%
ZyVersa Therapeutics	N/A	-109.54%	-43.95%

ZyVersa Therapeutics has lower revenue, but higher earnings than Flora Growth. ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Flora Growth	$57.61M	0.08	-$15.91M	-$32.49	N/A
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A

36.0% of Flora Growth shares are owned by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are owned by institutional investors. 2.3% of Flora Growth shares are owned by company insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Flora Growth has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market. Comparatively, ZyVersa Therapeutics has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

In the previous week, Flora Growth's average media sentiment score of 0.00 equaled ZyVersa Therapeutics'average media sentiment score.

Company	Overall Sentiment
Flora Growth	Neutral
ZyVersa Therapeutics	Neutral

Summary

Flora Growth beats ZyVersa Therapeutics on 10 of the 13 factors compared between the two stocks.

Get ZyVersa Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZVSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZVSA vs. The Competition

Export

Metric	ZyVersa Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.55M	$3.38B	$6.48B	$12.36B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-0.23	20.03	23.95	24.60
Price / Sales	N/A	320.04	536.37	171.61
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	0.06	8.01	10.44	6.77
Net Income	-$9.41M	$23.89M	$3.56B	$337.32M
7 Day Performance	11.49%	2.12%	0.83%	2.06%
1 Month Performance	5.41%	0.09%	1.78%	3.93%
1 Year Performance	-70.10%	44.59%	25.59%	32.29%

ZyVersa Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZVSA ZyVersa Therapeutics	N/A	$0.20 flat	N/A	-70.1%	$1.55M	N/A	N/A	2
SPRC SciSparc	0.4757 of 5 stars	$11.54 +22.0%	N/A	-85.9%	$5.35M	$860K	N/A	4	Gap Up High Trading Volume
INM InMed Pharmaceuticals	1.7682 of 5 stars	$1.56 -1.9%	N/A	-40.3%	$5.27M	$4.94M	N/A	10	Positive News
GELS Gelteq	0.9166 of 5 stars	$0.51 +5.8%	N/A	-52.9%	$5.20M	$110K	N/A	N/A	Short Interest Decrease Gap Up
RDHL Redhill Biopharma	1.0174 of 5 stars	$1.00 flat	N/A	-53.7%	$5.19M	$290K	0.00	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZVSA) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ZyVersa Therapeutics (ZVSA) Competitors

ZVSA vs. SPRC, INM, GELS, RDHL, and FLGC

How does ZyVersa Therapeutics compare to SciSparc?

Summary

How does ZyVersa Therapeutics compare to InMed Pharmaceuticals?

Summary

How does ZyVersa Therapeutics compare to Gelteq?

Summary

How does ZyVersa Therapeutics compare to Redhill Biopharma?

Summary

How does ZyVersa Therapeutics compare to Flora Growth?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVSA vs. The Competition

ZyVersa Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ZyVersa Therapeutics (ZVSA) Competitors

ZVSA vs. SPRC, INM, GELS, RDHL, and FLGC

How does ZyVersa Therapeutics compare to SciSparc?

Is ZVSA or SPRC more profitable?

Do analysts recommend ZVSA or SPRC?

Do insiders & institutionals have more ownership in ZVSA or SPRC?

Which has better earnings and valuation, ZVSA or SPRC?

Does the media prefer ZVSA or SPRC?

Which has more volatility & risk, ZVSA or SPRC?

Summary

How does ZyVersa Therapeutics compare to InMed Pharmaceuticals?

Do analysts rate INM or ZVSA?

Is INM or ZVSA more profitable?

Does the media prefer INM or ZVSA?

Which has preferable earnings and valuation, INM or ZVSA?

Do institutionals and insiders have more ownership in INM or ZVSA?

Which has more risk & volatility, INM or ZVSA?

Summary

How does ZyVersa Therapeutics compare to Gelteq?

Is ZVSA or GELS more profitable?

Does the media refer more to ZVSA or GELS?

Do analysts rate ZVSA or GELS?

Which has more risk and volatility, ZVSA or GELS?

Which has higher earnings and valuation, ZVSA or GELS?

Do institutionals & insiders have more ownership in ZVSA or GELS?

Summary

How does ZyVersa Therapeutics compare to Redhill Biopharma?

Do institutionals and insiders hold more shares of RDHL or ZVSA?

Does the media favor RDHL or ZVSA?

Do analysts recommend RDHL or ZVSA?

Is RDHL or ZVSA more profitable?

Which has more risk and volatility, RDHL or ZVSA?

Which has higher earnings & valuation, RDHL or ZVSA?

Summary

How does ZyVersa Therapeutics compare to Flora Growth?

Do analysts prefer FLGC or ZVSA?

Is FLGC or ZVSA more profitable?

Which has better earnings and valuation, FLGC or ZVSA?

Do insiders & institutionals believe in FLGC or ZVSA?

Which has more volatility & risk, FLGC or ZVSA?

Does the media prefer FLGC or ZVSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVSA vs. The Competition

ZyVersa Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools